Three Years After CARMENA: What Have We Learned?

Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2021-10, Vol.80 (4), p.425-427
Hauptverfasser:	Roussel, Eduard, Beuselinck, Benoit, Albersen, Maarten
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - surgery Cytoreduction Surgical Procedures Cytoreductive nephrectomy Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - surgery Life Sciences & Biomedicine Nephrectomy Renal cell carcinoma Science & Technology Treatment Outcome Urology & Nephrology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.
ISSN:	0302-2838 1873-7560
DOI:	10.1016/j.eururo.2021.07.007